Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 5/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 5/20 | 0.39 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.39 |
| ▸ | PDE2A | O00408 | 3/20 | 0.39 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.36 |
| ▸ | ACACA | Q13085 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15919392 | 0.92 | LTB4R (0.38) | FFAR4PDE3BPDE3AP2RY12PDE2A | |
| SCHEMBL15919390 | 0.91 | HDAC1 (0.44) | — | |
| SCHEMBL15905073 | 0.91 | XDH (0.45) | PDE3BPDE3AP2RY12PDE2APLA2G2A | |
| SCHEMBL15905108 | 0.90 | PDE3B (0.42) | PDE3BPDE3AP2RY12PLA2G2APDE10A | |
| SCHEMBL18897050 | 0.84 | FFAR4 (0.37) | FFAR4PDE3BPDE3AP2RY12PDE2A | |
| SCHEMBL15919391 | 0.84 | HDAC1 (0.44) | — | |
| SCHEMBL15919358 | 0.83 | XDH (0.43) | PDE3BPDE3AP2RY12PDE2APLA2G2A | |
| SCHEMBL15919398 | 0.83 | PDE3B (0.41) | PDE3BPDE3AP2RY12PLA2G2APDE10A | |
| Hydrochloric Acid SCHEMBL15905167 | 0.82 | XDH (0.43) | PDE3BPDE3AP2RY12PDE2APLA2G2A | |
| SCHEMBL15905376 | 0.81 | MEN1 (0.44) | PDE3BPDE3AXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | claimed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | claimed |
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
| WO-2014117090-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2014-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | FFAR4 4769/4885PDE3B 2232/4885PDE3A 3019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.